University Polyclinic Hospital of Modena
Welcome,         Profile    Billing    Logout  
 4 Trials 
5 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mussini, Cristina
MARIO, NCT05178862 / 2022-000648-32: A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole

Suspended
3
220
Europe, Canada, US, RoW
SCY-078, Ibrexafungerp, Fluconazole, Diflucan, Echinocandin, Caspofungin, Micafungin, Anidulafungin
Scynexis, Inc., SCYNEXIS, Inc.
Candidiasis, Invasive, Candidemia
06/24
08/24
OASIS, NCT05101187: Olorofim Aspergillus Infection Study

Recruiting
3
225
Europe, Canada, Japan, US, RoW
Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B)
F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi
Invasive Aspergillosis
09/25
11/26
NCT06061081: A Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in in Treatment-Naive Adults Living With HIV-1

Suspended
2
26
Europe, US, RoW
VH3739937, Placebo
ViiV Healthcare
HIV Infections
11/24
11/24
NCT04090151: The RESPOND Outcomes Study

Recruiting
N/A
37853
Europe, RoW
Rigshospitalet, Denmark, Gilead Sciences, ViiV Healthcare
HIV
12/25
12/25
Nardini, Giulia
MARIO, NCT05178862 / 2022-000648-32: A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole

Suspended
3
220
Europe, Canada, US, RoW
SCY-078, Ibrexafungerp, Fluconazole, Diflucan, Echinocandin, Caspofungin, Micafungin, Anidulafungin
Scynexis, Inc., SCYNEXIS, Inc.
Candidiasis, Invasive, Candidemia
06/24
08/24

Download Options